Aptevo Therapeutics Inc. (NASDAQ:APVO) Short Interest Update

Aptevo Therapeutics Inc. (NASDAQ:APVO) was the recipient of a significant decline in short interest in the month of December. As of December 31st, there was short interest totaling 139,996 shares, a decline of 86.5% from the December 15th total of 1,033,317 shares. Based on an average trading volume of 135,792 shares, the short-interest ratio is currently 1.0 days. Currently, 15.0% of the company’s shares are sold short. Currently, 15.0% of the company’s shares are sold short. Based on an average trading volume of 135,792 shares, the short-interest ratio is currently 1.0 days.

Institutional Investors Weigh In On Aptevo Therapeutics

A hedge fund recently bought a new stake in Aptevo Therapeutics stock. Birchview Capital LP acquired a new position in shares of Aptevo Therapeutics Inc. (NASDAQ:APVO) in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor acquired 10,000 shares of the biotechnology company’s stock, valued at approximately $30,000. Birchview Capital LP owned about 1.32% of Aptevo Therapeutics at the end of the most recent reporting period. Hedge funds and other institutional investors own 8.06% of the company’s stock.

Aptevo Therapeutics Stock Performance

NASDAQ APVO traded down $0.69 during trading on Monday, hitting $8.97. The stock had a trading volume of 176,532 shares, compared to its average volume of 420,187. Aptevo Therapeutics has a 12 month low of $7.66 and a 12 month high of $1,807.20. The company’s 50-day moving average price is $19.38 and its two-hundred day moving average price is $30.97. The company has a market capitalization of $8.43 million, a PE ratio of -0.01 and a beta of 1.47.

Aptevo Therapeutics (NASDAQ:APVO) last issued its quarterly earnings results on Thursday, November 6th. The biotechnology company reported ($40.14) earnings per share for the quarter, missing the consensus estimate of ($37.62) by ($2.52). As a group, equities analysts anticipate that Aptevo Therapeutics will post -15.84 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several research firms have recently weighed in on APVO. Roth Capital upgraded Aptevo Therapeutics to a “strong-buy” rating in a report on Tuesday, September 16th. Zacks Research upgraded shares of Aptevo Therapeutics to a “hold” rating in a report on Thursday, September 18th. Finally, Weiss Ratings reiterated a “sell (e)” rating on shares of Aptevo Therapeutics in a report on Monday, December 29th. One analyst has rated the stock with a Strong Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Hold”.

Aptevo Therapeutics Company Profile

Aptevo Therapeutics, Inc is a clinical-stage biopharmaceutical company headquartered in Seattle, Washington, focused on the discovery and development of novel immunotherapies for oncology and autoimmune diseases. Founded in 2012 as a spin-off from Emergent BioSolutions, the company builds on expertise in protein engineering and translational research to create targeted biologics that engage the body’s immune system.

The company’s core technologies include the ADAPTIR platform, which enables the design of bispecific and multispecific protein scaffolds with customizable binding domains, and the KNOCKOUT platform, which incorporates non-natural amino acids to enhance therapeutic properties such as stability and half-life.